Cybin, Bright Minds And PharmAla: A Short Recap On Progress Within Clinical Trials
Portfolio Pulse from Lara Goldstein
Cybin (NYSE:CYBN) has completed dosing on five of six participant cohorts in its ongoing Phase 2 trial for the treatment of Major Depressive Disorder (MDD). Bright Minds Biosciences (NASDAQ:DRUG) has completed its three-part Phase 1 clinical trial of BMB-101, a novel treatment for refractory epilepsies, psychosis, addiction and impulse control disorders. PharmAla Biotech Holdings (OTC:PMBHF) has received written guidance from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to proceed to clinical trials with MDMA analog ALA-002.
July 24, 2023 | 9:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cybin has completed dosing on five of six participant cohorts in its ongoing Phase 2 trial for the treatment of MDD.
The completion of dosing brings Cybin closer to establishing a therapeutically efficacious dose and advancing CYB003 toward FDA-approved pivotal studies. This is likely to have a positive impact on the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Bright Minds Biosciences has completed its three-part Phase 1 clinical trial of BMB-101, a novel treatment for refractory epilepsies, psychosis, addiction and impulse control disorders.
The completion of the Phase 1 trial and the positive clinical data for BMB-101 is likely to have a positive impact on the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
PharmAla Biotech Holdings has received written guidance from the UK’s MHRA to proceed to clinical trials with MDMA analog ALA-002.
The approval from MHRA to proceed to clinical trials with ALA-002 is likely to have a positive impact on the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100